Androxal has predicted cost of $2000 per year !

Posted: 2010 in Androxal, Enclomiphene citrate, hypogonadism

Assuming a conservative addressable market of just 350,000 men for Androxal for the treatment of secondary hypogonadism, the potential market size could be in excess of $700 million annually based on an annual treatment cost of $2,000 per patient. Meanwhile, the company anticipates capturing a large portion of the market given its oral treatment with no black box warnings, no partner risk, and no controlled substances.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s